Battelle announced today that it entered into a collaborative agreement with Spark Biomedical to jointly run a pilot clinical study.
Through the joint study, the two companies aim to advance the remote detection and treatment of opioid use disorder (OUD) using wearable biosensors.
According to a news release, the study’s primary objective is to collect physiological data from the biosensors for patients experiencing opioid withdrawal symptoms, cravings and addiction-related physiological stressors using the Battelle NeuroHub system. Once data is acquired, the team will develop an artificial intelligence (AI) algorithm to detect withdrawal using objective physiological biomarkers.
Once the study is completed, Spark and Battelle intend to use the resulting AI algorithm to develop a new, more objective physiological assessment tool for opioid withdrawal measurement, as well as to develop AI and machine learning algorithms for understanding mental heal…